Navigation Links
Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
Date:8/25/2011

with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy – practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com.

This press release contains forward-looking statements about linagliptin tablets for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that linagliptin will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

P-LLY

TJ110702PR

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO)

(1)Trajenta™ (linagliptin) tablets. EMA Summary of Product Characteristics. 2011.

(
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
2. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
3. Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 2014  Actavis plc (NYSE: ACT ), a ... Saunders , CEO and President of Actavis, will provide an ... Stanley Global Healthcare Conference 2014 in New York, ... The presentation will take place on Tuesday, September ... Hyatt New York, 109 East 42 nd Street, ...
(Date:8/26/2014)... Research and Markets  has announced the ... 2014-2018" report to their offering. Intranasal ... the administration of drugs for the treatment of local ... allergic and non-allergic rhinitis and sinusitis. The nose is ... vaccination and systematic drug delivery. Continuous ...
(Date:8/26/2014)... comes to diabetes supplies, innovations are often accused of ... answer a real medical need. Fitting ... shows how long it,s been since your last injection. ... insulin doses. Very easy to use, Timesulin starts automatically ... after an injection. There is no settings or complicated ...
Breaking Medicine Technology:Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2
(Date:8/27/2014)... 27, 2014 ALS Insights is a ... and comfort. It features a series of compelling interviews ... They share their insights, in searing honesty, about issues ... impact on children, what happened in the final days ... Challenge has created a dramatic increase in public awareness ...
(Date:8/27/2014)... Lake City, Utah (PRWEB) August 27, 2014 ... in advancing the business of healthcare, is pleased ... , a ground-breaking online recruitment resource specifically designed ... hiring is undergoing significant changes. To help address ... aging workforce, and tighter budgets—AAPC launched CareerHealth.com ...
(Date:8/27/2014)... CT (PRWEB) August 27, 2014 ... cyclists of all abilities to go the distance this ... Alex’s Million Mile – Run. Walk. Ride. initiative, hosted ... and increase awareness of childhood cancer. September represents ... year’s Alex’s Million Mile, Inspira Marketing Group has teamed ...
(Date:8/27/2014)... August 27, 2014 IntelliSoft Group, LLC, ... management software, will unveil IntelliCred, IntelliApp and ... of Medical Staff Services (NHAMSS) Annual Conference on September ... in Bedford, NH. , Notable improvements available in ... , Contract Linking: A new Contract Connection ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 A recently ... discusses the importance of time in correcting coagulopathy to ... on a variety of anticoagulants and examines medical conditions ... to the research, although anticoagulants have been approved by ... systemic embolism, they are also known to affect the ...
Breaking Medicine News(10 mins):Health News:ALS Insights Launched as Web Resource of Interviews and Information 2Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 2Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 3Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 3Health News:IntelliSoft Group to Unveil Version 14.2 of IntelliCred, IntelliApp and IntelliContract at the New Hampshire Association of Medical Staff Services Annual Conference 2Health News:Flood Law Group Comments on Recent AAICH Study 2
... treatment for recurrent Clostridium difficile infection (CDI), ... the official journal of the American Gastroenterological Association. Additionally, ... to be greater than in some previously reported series, ... rather safe procedure. CDI is a common cause of ...
... 14, 2012Research!America will honor some of our nation,s foremost ... Advocacy Awards tonight at the Andrew W. Mellon Auditorium ... leaders from government, industry, academia and health advocacy organizations ... have made an impact in advancing the nation,s commitment ...
... (HealthDay News) -- High school and college students around the country ... on vacation can ruin the fun. The American College of ... prevent injuries and stay safe while traveling with their friends or ... should go to the nearest ER so we can treat them," ...
... (HealthDay News) -- The drug misoprostol reduced major complications ... a new study. Doctors often use misoprostol for ... now, however, there were no studies large enough to ... complications, either immediate or delayed, according to background information ...
... , WEDNESDAY, March 7 (HealthDay News) -- Researchers report that ... system in patients who received kidney transplants, a process that ... organ instead of trying to reject it. There are ... number of patients. Also, the required procedure is expensive and ...
... Treatment with the common diabetes drug metformin appears ... infected with HIV. In a presentation today ... Infections, Massachusetts General Hospital (MGH) researchers reported that ... essentially no progression of coronary artery calcification during ...
Cached Medicine News:Health News:A new treatment option for Clostridium difficile: Fecal transplantation 2Health News:Research!America honors leading health research advocates 2Health News:Spring Break Safety Tips to Keep Vacation Fun 2Health News:Drug Reduces Complications in Surgical Abortions: Study 2Health News:Transplant Procedure Creates 'Hybrid' Immune System to Combat Rejection 2Health News:Transplant Procedure Creates 'Hybrid' Immune System to Combat Rejection 3Health News:Diabetes drug halts atherosclerosis progression in HIV-infected patients 2Health News:Diabetes drug halts atherosclerosis progression in HIV-infected patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: